SCHEMBL583350

SCHEMBL583350

CCn1ncc2c(Nc3ncccn3)c(C3=NOC4(CCC4)C3)cnc21

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 17/20 0.39
PDE7A Q13946 2/20 0.39
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
XDH P47989 1/20 0.32
PDE5A O76074 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL583266 0.98 PDE4B (0.39) PDE4BPDE7APDE3BPDE3AXDH
SCHEMBL582423 0.97 PDE4B (0.40) PDE4BPDE7APDE3BPDE3AXDH
SCHEMBL582390 0.91 PDE4B (0.37) PDE4BPDE7APDE3BPDE3A
SCHEMBL582601 0.89 PDE4B (0.38) PDE4BPDE7APDE3BPDE3A
SCHEMBL583472 0.89 PDE4B (0.37) PDE4BPDE7APDE3BPDE3A
SCHEMBL582190 0.89 PDE4B (0.48) PDE4BPDE7APDE3BPDE3AMAPT
SCHEMBL582111 0.88 PDE4B (0.38) PDE4BPDE7APDE3BPDE3A
SCHEMBL582472 0.88 PDE4B (0.39) PDE4BPDE7APDE3BPDE3AXDH
SCHEMBL583063 0.87 PDE4B (0.40) PDE4BPDE7APDE3BPDE3AMAPT
SCHEMBL582386 0.87 PDE4B (0.37) PDE4BPDE7APDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US claimed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP claimed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US claimed
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US disclosed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP disclosed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4A, PDE3A PDE4B 5/4885PDE7A 4/4885PDE3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.